FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

61 letters match. Newest first.

  1. Exactech, Inc. dba Advita Ortho

    FDA warned Exactech/Advita Ortho over quality-system failures in Equinoxe shoulder implants found during a July 2025 Sarasota inspection.

    High risk
  2. AQ USA Inc., d.b.a Ross Healthcare Inc.

    FDA warns AQ USA/Ross Healthcare over current good manufacturing practice violations in drugs, including missing microbial testing and inadequate component and stability controls.

    High risk
  3. Cosmetic Manufacturers Pty Ltd.

    FDA warned Cosmetic Manufacturers Pty Ltd. that its Australian drug site was adulterated due to CGMP violations and placed its drugs on import alert.

    High risk
  4. Flextronics America LLC

    FDA warns Flextronics America, contract maker of FreeStyle Libre 3 glucose sensors in Austin, TX, over an unvalidated assembly step and weak corrective actions.

    High risk
  5. Abbott Diabetes Care, Inc.

    FDA warns Abbott Diabetes Care that FreeStyle Libre 3 glucose monitors lacked design transfer and finished-device accuracy release testing.

    High risk
  6. CC Pollen Company

    FDA warns CC Pollen Company of Glendale, Arizona, that its bee pollen and royal jelly supplements are adulterated and misbranded.

    High risk
  7. Eniva USA, Inc.

    FDA warns Eniva USA over manufacturing quality failures for Immune Support and Ashwagandha Gummies.

    Medium
  8. LXR Biotech, LLC

    FDA warns LXR Biotech over CGMP (manufacturing quality rules) failures for Eternal Energy supplements, making them adulterated (legally unfit as made).

    Medium
  9. LiquidCapsule Manufacturing, LLC

    LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.

    High risk
  10. Unipack LLC

    FDA says Unipack LLC released suppositories without adequate out-of-specification investigations, complete lab records, and required USP testing.

    High risk
  11. SV Labs Corporation

    SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.

    High risk